Becker's Healthcare October 21, 2024
Novo Nordisk’s GLP-1 medication, Rybelsus, reduced major adverse cardiovascular events by 14% compared to a placebo in a phase 3 trial, the drugmaker said Oct. 21.
Rybelsus, a daily pill approved in 2019 for Type 2 diabetes, contains the same active ingredient as Ozempic and Wegovy.
The study enrolled 9,650 Type 2 diabetes patients who have cardiovascular disease and/or chronic kidney disease. The primary outcome was defined by the first occurrence of...
Today's Sponsors
Today's Sponsor